OVERVIEW

Live Webinar: Part 1 - Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma is organized by i3 Health and will be held on Jan 11, 2022.

Target Audience:
Hematologists, oncologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with multiple myeloma (MM).

Statement of Need:
Multiple myeloma is a B-cell neoplasm that occurs primarily in older adults. The incidence is expected to rise in conjunction with the aging population. Because symptoms often do not appear until the malignancy is in advanced stages, early diagnosis is difficult, and the 5-year relative survival rate remains only 54% (ACS, 2021). Following diagnosis, management must be guided by cytogenic markers with prognostic significance and correct staging based upon these markers (NCCN, 2019). As recommendations change with the fast pace of multiple myeloma research, it is difficult to stay abreast of new developments (i3 Health, 2021). In this webinar, Sarah Holstein, MD, PhD, and Ashley Rosko, MD, will discuss the latest recommendations for multiple myeloma classification at diagnosis, new data on treatment regimens for newly diagnosed disease, and strategies for maintenance therapy.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess factors that classify patients as high risk in multiple myeloma development and progression
• Appraise emerging efficacy and safety data on novel combination therapies for newly diagnosed multiple myeloma in transplant-eligible and transplant-ineligible patients
• Develop strategies for maintenance therapy that incorporate emerging data

Faculty
• Sarah A. Holstein, MD
Associate Professor
Division of Oncology and Hematology
Univeristy of Nebraska Medical Center

• Ashley E. Rosko, MD
Associate Professor of Medicine
Medical Director of Oncogeriatrics
The Ohio State University
The James Comprehensive Cancer Center

This two-part live webinar series led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Part 1 of this series will take an in-depth look at the new standards in multiple myeloma classification at diagnosis, recent data on treatment regimens for newly diagnosed disease, and strategies for maintenance therapy.